FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease

SILVER SPRING, Md., April 10, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic disorder of the nervous system causing tumors...

from PR Newswire: https://ift.tt/2VcKKSU